Financial News Search | Sharemaestro Newsreel

08:00 29 Jul 2026

finance.yahoo.com Regulatory and legal Main company 🇦🇷 Argentina

AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Non-Segmental Vitiligo

RINVOQ is the first and only systemic medication approved in the European Union to treat adult and adolescent patients with non-segmental vitiligo (NSV) The approval is supported by data from the Phase 3 Viti-Up clinical program, which showed that RINVOQ achieved statistically significant total …

ABBV main company ABBV main company ABBV34 main company ABBV main company ABBV main company

Sharemaestro market context Trend signal active 52 weeks +40.4% · Next-week setup negative 42.8%

07:59 29 Jul 2026

Stock Titan Market update Main company 🇦🇷 Argentina

EU Approves AbbVie's RINVOQ After Trials Show Complete Scalp Hair Regrowth

The European Commission has approved AbbVie's RINVOQ (upadacitinib) for treating severe alopecia areata in adults and adolescents aged 12 and older. This approval is supported by Phase 3 trials where RINVOQ demonstrated significant scalp hair regrowth, including complete regrowth in some patients, at both …

ABBV main company ABBV main company

Sharemaestro market context Trend signal active 52 weeks +40.4% · Next-week setup negative 42.8%

03:00 29 Jul 2026

PR Newswire Market update Main company 🇺🇸 United States

AbbVie Announces Availability of ELAHERE® (mirvetuximab soravtansine) in Singapore for the Treatment of Platinum-Resistant Ovarian Cancer

AbbVie has announced the availability of ELAHERE (mirvetuximab soravtansine) in Singapore for treating platinum-resistant ovarian cancer. This antibody-drug conjugate (ADC) is the first and only one approved for patients with FRα-positive high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who have undergone …

ABBV main company

Sharemaestro market context Trend signal active 52 weeks +21.3% · Next-week setup positive 57.6%

19:59 28 Jul 2026

Sharemaestro Market Watch Insider activity Main company 🇺🇸 United States

AbbVie Inc (ABBV) director adds stock-equivalent units after 25.5% 12-week rise

The insider acquisition lands with the biopharma stock still in an active weekly trend, though latest volume ran below its 13-week average.

ABBV main company

Sharemaestro market context Trend signal active 52 weeks +21.3% · Next-week setup positive 57.6%

19:40 28 Jul 2026

finance.yahoo.com Deals and strategy Main company 🇦🇷 Argentina

Botox Maker Tops Buy Point, But Here Comes The Earnings Report

AbbVie closed above the 230.47 buy point from a cup-with-handle base on June 23 and has climbed 15% from there. The previous day, the stock jumped more than 6% after AbbVie announced it agreed to acquire Apogee Therapeutics. The $10.9 billion deal would strengthen …

ABBV main company ABBV main company ABBV34 main company ABBV main company ABBV main company

Sharemaestro market context Trend signal active 52 weeks +40.4% · Next-week setup negative 42.8%

18:06 28 Jul 2026

TradingView Earnings Main company 🇦🇷 Argentina

Should You Buy, Hold or Sell ABBV Stock Ahead of Q2 Earnings?

AbbVie ABBV is set to report second-quarter 2026 earnings on July 31, before the opening bell. The Zacks Consensus Estimate for the to-be-reported quarter's sales is pinned at $16.81 billion, while earnings per share (EPS) are estimated at $3.66. Both metrics indicate an increase …

ABBV main company ABBV main company ABBV34 main company ABBV main company ABBV main company

Sharemaestro market context Trend signal active 52 weeks +40.4% · Next-week setup negative 42.8%

17:31 28 Jul 2026

MarketWatch Earnings Main company 🇺🇸 United States

AbbVie Inc. stock outperforms competitors on strong trading day

AbbVie Inc. (ABBV) stock advanced 2.45% to $263.20 on Tuesday, outperforming the S&P 500 Index and the Dow Jones Industrial Average. The company also reached a new 52-week high, exceeding its previous peak from the day before.

ABBV main company

Sharemaestro market context Trend signal active 52 weeks +21.3% · Next-week setup positive 57.6%

16:16 28 Jul 2026

TradingKey Earnings Main company 🇲🇽 Mexico

AbbVie Inc Stock (ABBV) Moved Up by 3.35% on Jul 28: A Full Analysis

AbbVie Inc (ABBV) saw its stock rise by 3.35% on July 28, outperforming the Pharmaceuticals & Medical Research sector. This strong performance was attributed to robust second-quarter earnings, significant growth in its immunology drugs Skyrizi and Rinvoq, and positive late-stage clinical trial data in …

ABBV main company ABBV main company

Sharemaestro market context Trend signal active 52 weeks +9.6%

12:45 28 Jul 2026

www.marketscreener.com Analyst action Main company 🇺🇸 United States

Barclays Adjusts AbbVie PT to $300 From $275, Maintains Overweight Rating

Barclays has increased its price target for AbbVie (ABBV) to $300 from $275, while reiterating an Overweight rating on the stock. The adjustment reflects an updated outlook from the analytical firm regarding the pharmaceutical company's future performance. AbbVie specializes in therapeutic drug research and …

ABBV main company

Sharemaestro market context Trend signal active 52 weeks +21.3% · Next-week setup positive 57.6%

16:36 27 Jul 2026

Fierce Pharma Market update Main company 🇺🇸 United States

Sarepta taps AbbVie, Tessera vet Severino to write Duchenne firm's next chapter

Sarepta Therapeutics has appointed Michael Severino, former vice chairman at AbbVie and CEO of Tessera Therapeutics, as its new chief executive, effective Tuesday. Severino replaces Doug Ingram, who is retiring due to family health issues. Severino will face the challenge of navigating commercial realities …

ABBV main company

Sharemaestro market context Trend signal active 52 weeks +21.3% · Next-week setup positive 57.6%

16:33 27 Jul 2026

BioPharma Dive Earnings Main company 🇺🇸 United States

Sarepta, in search of a turnaround, taps ex-AbbVie exec Severino as CEO

Sarepta Therapeutics has appointed Michael Severino, an executive with experience at AbbVie and Amgen and most recently Tessera Therapeutics, as its new CEO, effective July 28. Severino faces the challenge of turning around Sarepta's fortunes, as the company has lost significant market value over …

ABBV main company

Sharemaestro market context Trend signal active 52 weeks +21.3% · Next-week setup positive 57.6%

15:24 27 Jul 2026

BioSpace Deals and strategy Main company 🇺🇸 United States

Sarepta names former AbbVie R&D exec Michael Severino as next CEO

Sarepta Therapeutics has appointed Michael Severino, formerly of Tessera Therapeutics and AbbVie, as its new CEO, succeeding Doug Ingram. Severino takes the helm at a critical juncture as Sarepta awaits two key FDA decisions for its Duchenne muscular dystrophy drugs, Amondys 45 and Vyondys …

ABBV main company

Sharemaestro market context Trend signal active 52 weeks +21.3% · Next-week setup positive 57.6%

14:43 27 Jul 2026

Investing.com Earnings Main company 🇧🇷 Brazil

AbbVie stock hits all-time high of 261.71 USD

AbbVie Inc. (ABBV) stock has reached a new all-time high of $261.71, reflecting a 40.53% total return over the past year. Despite being considered slightly overvalued by InvestingPro analysis, the company demonstrates strong financial health with 9.5% revenue growth. Upcoming earnings on July 31st …

ABBV34 main company ABBV main company

Sharemaestro market context Trend signal active 52 weeks +16.4%

14:36 27 Jul 2026

TIKR.com Deals and strategy Main company 🇺🇸 United States

Is AbbVie Stock a Buy After Its $10.9 Billion Apogee Bet

AbbVie (ABBV) recently acquired Apogee Therapeutics for $10.9 billion, a move that is expected to dilute adjusted EPS until 2032 but aims for a "mega blockbuster" drug, zumilokibart, targeting over $10 billion in peak sales. Despite the near-term dilution, AbbVie stock has largely recovered …

ABBV main company ABBV main company

Sharemaestro market context Trend signal active 52 weeks +21.3% · Next-week setup positive 57.6%

14:19 27 Jul 2026

Reuters Earnings Main company 🇺🇸 United States

Sarepta names former Abbvie president as CEO as Ingram retires

Sarepta Therapeutics has appointed Michael Severino, former Tessera Therapeutics CEO and a longtime AbbVie executive, as its new chief executive, effective July 28. Severino will succeed Doug Ingram, who is stepping down after leading Sarepta since 2017 but will remain in an advisory role …

ABBV main company

Sharemaestro market context Trend signal active 52 weeks +21.3% · Next-week setup positive 57.6%

14:07 27 Jul 2026

Stock Traders Daily Market update Main company 🇺🇸 United States

How Abbvie Inc. (ABBV) Affects Rotational Strategy Timing

This article from Stock Traders Daily analyzes Abbvie Inc. (ABBV) and its impact on rotational strategy timing. It highlights a neutral sentiment for ABBV across all horizons, suggesting a wait-and-see approach, and identifies no resistance levels above the current price, indicating potential upside. The …

ABBV main company

Sharemaestro market context Trend signal active 52 weeks +21.3% · Next-week setup positive 57.6%

17:09 25 Jul 2026

Market source Earnings Main company 🇦🇷 Argentina

AbbVie (ABBV) Could Be 3% Undervalued Following Epcoritamab Trial Setback

AbbVie (ABBV) may be 3% undervalued despite a recent setback in the Phase 3 EPCORE DLBCL-1 trial for its drug epcoritamab. The company's diverse pipeline and strong cash generation suggest potential for future growth, with a fair value estimated at $266.89 against a last …

ABBV main company ABBV main company ABBV main company

Sharemaestro market context Trend signal active 52 weeks +40.4% · Next-week setup negative 42.8%

13:07 25 Jul 2026

AD HOC NEWS Deals and strategy Main company 🇺🇸 United States

AbbVie stock trades steadily as Humira erosion meets Skyrizi and Rinvoq growth

AbbVie Inc. is managing a transition as its blockbuster drug Humira faces declining sales due to biosimilar competition. The company is actively offsetting this revenue loss with the strong growth of newer immunology drugs, Skyrizi and Rinvoq, which are showing double-digit percentage growth. Investors …

ABBV main company

Sharemaestro market context Trend signal active 52 weeks +21.3% · Next-week setup positive 57.6%

11:37 25 Jul 2026

Trefis Market update Main company 🇺🇸 United States

Should You Pay Attention To AbbVie Stock's Momentum?

The article poses a question about whether investors should pay attention to AbbVie stock's momentum. However, the provided content is largely navigational, legal disclaimers, and technical limitations of an interactive model, without any actual article text or financial analysis regarding AbbVie. It does not …

ABBV main company

Sharemaestro market context Trend signal active 52 weeks +21.3% · Next-week setup positive 57.6%

08:07 25 Jul 2026

Investing.com Earnings Main company 🇺🇸 United States

AbbVie stock may move 4.2% on July 31 earnings report

AbbVie Inc. (NYSE:ABBV) stock is projected to move by 4.2% based on options data ahead of its July 31 earnings release. Historically, the stock's actual movement has often exceeded the implied move from options. The article details past earnings announcement performances, noting instances where …

ABBV main company

Sharemaestro market context Trend signal active 52 weeks +21.3% · Next-week setup positive 57.6%

15:06 24 Jul 2026

Market source Earnings Main company 🇦🇷 Argentina

AbbVie (ABBV) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

AbbVie (ABBV) is expected to report a year-over-year increase in earnings and higher revenues for the quarter ended June 2026, with results anticipated on July 31. The consensus EPS estimate is $3.66 per share (+23.2% year-over-year) and revenues are projected at $16.81 billion (+9%). …

ABBV main company ABBV main company ABBV34 main company ABBV main company ABBV main company

Sharemaestro market context Trend signal active 52 weeks +40.4% · Next-week setup negative 42.8%

12:53 24 Jul 2026

Benzinga Earnings Main company 🇺🇸 United States

CNBC ‘Final Trades’: Netflix, AbbVie, Cerebras Systems - Netflix (NASDAQ:NFLX), CrowdStrike Holdings (NAS

This article summarizes the "Final Trades" segment on CNBC, highlighting stock picks from various financial experts. Recommendations include AbbVie (ABBV) with a raised price target, Transocean (RIG) ahead of earnings, Cerebras Systems (CBRS) due to a new cybersecurity partnership with CrowdStrike (CRWD), and Netflix …

ABBV main company

Sharemaestro market context Trend signal active 52 weeks +21.3% · Next-week setup positive 57.6%

09:25 24 Jul 2026

TradingKey Earnings Main company 🇺🇸 United States

ABBV|AbbVie Inc|Price:256.910|Chg%:+3.610

AbbVie Inc. (ABBV) shows stable fundamentals and high growth potential, with its valuation considered fairly valued within the Pharmaceuticals industry. The stock is a high dividend payer and exhibits high institutional ownership. While the stock price is expected to trend upwards in the medium …

ABBV main company

Sharemaestro market context Trend signal active 52 weeks +21.3% · Next-week setup positive 57.6%

08:11 24 Jul 2026

The Clinical Trial Vanguard Market update Main company 🇺🇸 United States

Genmab, AbbVie Clarify Epcoritamab Phase 3 Trial Missed Primary Endpoint

Genmab and AbbVie issued a clarification regarding their Phase 3 EPCORE DLBCL-1 trial, stating that overall survival was the sole U.S. primary endpoint and it was not met. This clarification was deemed necessary due to interpretive ambiguity in earlier disclosures, highlighting the complexities of …

ABBV main company

Sharemaestro market context Trend signal active 52 weeks +21.3% · Next-week setup positive 57.6%

23:11 23 Jul 2026

Moomoo Market update Main company 🇺🇸 United States

Genmab, AbbVie Say Lymphoma Drug Failed to Meet Primary Endpoint in Phase 3 Trial

Genmab and AbbVie announced that their lymphoma drug, epcoritamab, did not meet the primary endpoint in a Phase 3 clinical trial. The trial aimed to evaluate the drug's efficacy in patients with diffuse large B-cell lymphoma (DLBCL). This outcome is a setback for the …

ABBV main company

Sharemaestro market context Trend signal active 52 weeks +21.3% · Next-week setup positive 57.6%

21:10 23 Jul 2026

The Manila Times Market update Main company 🇺🇸 United States

Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Genmab and AbbVie clarified that overall survival (OS) was the sole U.S. primary endpoint for the Phase 3 EPCORE DLBCL-1 trial, which unfortunately did not meet this endpoint, indicating no statistically significant improvement in OS. The study evaluated epcoritamab in adults with relapsed or …

ABBV main company

Sharemaestro market context Trend signal active 52 weeks +21.3% · Next-week setup positive 57.6%

21:00 23 Jul 2026

Stock Titan Market update Main company 🇺🇸 United States

Epcoritamab U.S. Lymphoma Trial Does Not Meet Survival Endpoint

Genmab and AbbVie announced that their Phase 3 EPCORE® DLBCL-1 trial, evaluating epcoritamab for relapsed/refractory diffuse large B-cell lymphoma (DLBCL), did not meet its primary endpoint of overall survival in the U.S. market. While epcoritamab is already approved under accelerated pathways for similar conditions, …

ABBV main company

Sharemaestro market context Trend signal active 52 weeks +21.3% · Next-week setup positive 57.6%

17:04 23 Jul 2026

Seeking Alpha Earnings Main company 🇺🇸 United States

AbbVie: Bright Future, But Already Priced In (NYSE:ABBV)

AbbVie Inc. is rated a 'Hold' due to its slight overvaluation and high debt levels, despite strong Q1/26 revenue and free cash flow growth. The company's growth is largely driven by Skyrizi and Rinvoq, with pipeline diversification coming from Neuroscience and the Apogee Therapeutics …

ABBV main company

Sharemaestro market context Trend signal active 52 weeks +21.3% · Next-week setup positive 57.6%

21:07 22 Jul 2026

MarketWatch Market update Main company 🇺🇸 United States

AbbVie Inc. stock underperforms Wednesday when compared to competitors

AbbVie Inc. (ABBV) shares fell 1.09% on Wednesday, closing at $253.30, and underperformed the broader market, with both the S&P 500 and Dow Jones Industrial Average also seeing slight declines. The stock is currently 3.19% below its 52-week high reached earlier in July.

ABBV main company

Sharemaestro market context Trend signal active 52 weeks +21.3% · Next-week setup positive 57.6%

21:06 22 Jul 2026

TradingView Market update Main company 🇺🇸 United States

Total equity of AbbVie, Inc. – BCS:ABBV0

This article provides the total equity information for AbbVie, Inc. (BCS:ABBV0) from the Santiago Stock Exchange, accessed via TradingView. It indicates that the market was closed at the time of viewing and no trades were recorded. The content is primarily a data page with …

ABBV main company

Sharemaestro market context Trend signal active 52 weeks +21.3% · Next-week setup positive 57.6%

18:57 22 Jul 2026

Bloomberg Law News Regulatory and legal Main company 🇺🇸 United States

AbbVie Sues Galderma Over Patented Dermal Filler Syringe Designs

AbbVie Inc. and its Allergan Inc. unit have filed a patent infringement lawsuit against Galderma Group AG and Galderma SA. The lawsuit alleges that Galderma created dermal filler syringes for its Restylane product with a design similar to AbbVie's Juvéderm syringes, infringing on several …

ABBV main company

Sharemaestro market context Trend signal active 52 weeks +21.3% · Next-week setup positive 57.6%

18:06 22 Jul 2026

TradingView Earnings Main company 🇺🇸 United States

Will AbbVie's Oncology Franchise Remain Under Pressure in Q2?

AbbVie's oncology franchise is facing continued pressure, primarily due to declining Imbruvica sales, despite growth from newer therapies. The Zacks Consensus Estimate for Q2 oncology revenues suggests a slight decline from the previous year. The company's stock has outperformed the industry year-to-date, and it …

ABBV main company

Sharemaestro market context Trend signal active 52 weeks +21.3% · Next-week setup positive 57.6%

13:36 22 Jul 2026

Investing.com Canada Deals and strategy Main company 🇦🇷 Argentina

Canaccord raises Abbvie stock price target to $282 on growth outlook

Canaccord Genuity increased its stock price target for Abbvie Inc. (NYSE: ABBV) to $282 from $273, maintaining a Buy rating due to strong growth prospects. The firm anticipates a solid second quarter driven by prescription trends and the strategic $10 billion acquisition of APGE, …

ABBV main company ABBV main company ABBV34 main company ABBV main company ABBV main company

Sharemaestro market context Trend signal active 52 weeks +40.4% · Next-week setup negative 42.8%

12:54 22 Jul 2026

GuruFocus Analyst action Main company 🇺🇸 United States

ABBV Maintains Buy Rating -- Price Target Raised to $282 by Cana

Canaccord Genuity maintained a Buy rating for AbbVie (ABBV) and raised its price target from $273.00 to $282.00, reflecting confidence in the company's future performance. Despite the positive analyst outlook, GuruFocus indicates that ABBV is currently 20.3% overvalued with a GF Value™ of $212.81 …

ABBV main company

Sharemaestro market context Trend signal active 52 weeks +21.3% · Next-week setup positive 57.6%

10:40 22 Jul 2026

marketscreener.com Analyst action Main company 🇺🇸 United States

Canaccord Genuity Adjusts Price Target on AbbVie to $282 From $273, Maintains Buy Rating

Canaccord Genuity has increased its price target for AbbVie (ABBV) to $282 from $273, while reiterating a "Buy" rating on the stock. This adjustment reflects an updated outlook by the analyst firm on the pharmaceutical company. AbbVie specializes in therapeutic drug research and development, …

ABBV main company

Sharemaestro market context Trend signal active 52 weeks +21.3% · Next-week setup positive 57.6%

10:07 22 Jul 2026

TradingView Market update Main company 🇺🇸 United States

ETFs Investing in AbbVie, Inc. Stocks

This article lists various Exchange Traded Funds (ETFs) that hold AbbVie, Inc. stocks, providing key financial data for each. It includes details such as market value, weight of ABBV in the ETF, issuer, management style, expense ratio, assets under management (AUM), price, change percentage, …

ABBV main company

Sharemaestro market context Trend signal active 52 weeks +21.3% · Next-week setup positive 57.6%

168 matching headlines